ALEC Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 109270 min ago

@ $6.07

Ausgestellt: 13 Feb 2024 @ 21:46

Rendite: -12.17%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: -2.10 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:55):

Stats
Tagesvolumen	111 592
Durchschnittsvolumen	685 738
Marktkapitalisierung	510.44M
EPS	$0 ( 2024-02-27 )
Nächstes Ertragsdatum	( $-0.480 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.42
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)
2024-03-19	Desouza Errol B	Buy	41 250	Common Stock
2024-03-19	Desouza Errol B	Buy	19 420	Stock Option (right to buy)
2024-03-19	Altmeyer Mark	Sell	0	No securities of the Issuer are beneficially owned.

INSIDER POWER
-15.54
Last 100 transactions
Buy: 2 733 277 \| Sell: 3 561 219

Volumen Korrelation

Lang: -0.07 (neutral)

Kurz: 0.21 (neutral)

Signal:(27.214) Neutral

Alector Inc Korrelation

10 Am meisten positiv korreliert
UEIC	0.946
INGN	0.946
SPTN	0.942
NKTR	0.94
SSP	0.938
TUEM	0.931
AADI	0.931
MQ	0.929
GBNH	0.928
BAND	0.927

10 Am meisten negativ korreliert
XLRN	-0.935
ALR	-0.917
ORTX	-0.917
FLMN	-0.917
CPTA	-0.916
TYHT	-0.911
HILS	-0.91
MYRG	-0.909
INOD	-0.909
RESN	-0.906

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Alector Inc Korrelation - Währung/Rohstoff

0.34
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.24
( neutral )

Alector Inc Finanzdaten

Annual	2023
Umsatz:	$97.06M
Bruttogewinn:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2023
Umsatz:	$97.06M
Bruttogewinn:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2022
Umsatz:	$133.62M
Bruttogewinn:	$125.15M (93.66 %)
EPS:	$-1.620

FY	2021
Umsatz:	$207.09M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.467

Financial Reports:

No articles found.

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Echtzeitaktualisierungen für Alector Inc [ALEC]

Upcoming Earnings Alert